The short version of Albumin binding fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Linus Carl Pauling was born on February 28, 1901, in Portland, Oregon, the firstborn child of Herman Henry William Pauling (1876–1910) and Lucy Isabelle "Belle" Darling (1881–1926). He was named "Linus Carl", in honor of Lucy's father, Linus, and Herman's father, Carl. His ancestry included German and English-Scottish. In 1902, after his sister Pauline was born, Pauling's parents decided to move out of Portland to find more affordable and spacious living quarters than their one-room apartment. Lucy stayed with her husband's parents in Lake Oswego until Herman brought the family to Salem, where he worked briefly as a traveling salesman for the Skidmore Drug Company. Within a year of Lucile's birth in 1904, Herman Pauling moved his family to Lake Oswego, Oregon where he opened his own drugstore. He moved his family to Condon, Oregon, in 1905. By 1906, Herman Pauling was suffering from recurrent abdominal pain. He died of a perforated ulcer on June 11, 1910, leaving Lucy to care for Linus, Lucile and Pauline. Pauling attributes his interest in becoming a chemist to being amazed by experiments conducted by a friend, Lloyd A. Jeffress, who had a small chemistry lab kit. He later wrote: "I was simply entranced by chemical phenomena, by the reactions in which substances, often with strikingly different properties, appear; and I hoped to learn more and more about this aspect of the world." In high school, Pauling conducted chemistry experiments by scavenging equipment and material from an abandoned steel plant.
When Mullis developed the PCR in 1983, he was working in Emeryville, California for Cetus Corporation, one of the first biotechnology companies, where he was responsible for synthesizing short chains of DNA. Mullis has written that he conceived the idea for PCR while cruising along the Pacific Coast Highway one night in his car. He was playing in his mind with a new way of analyzing changes (mutations) in DNA when he realized that he had instead invented a method of amplifying any DNA region through repeated cycles of duplication driven by DNA polymerase. In Scientific American, Mullis summarized the procedure: "Beginning with a single molecule of the genetic material DNA, the PCR can generate 100 billion similar molecules in an afternoon. The reaction is easy to execute. It requires no more than a test tube, a few simple reagents, and a source of heat." DNA fingerprinting was first used for paternity testing in 1988. Mullis has credited his use of LSD as integral to his development of PCR: "Would I have invented PCR if I hadn't taken LSD? I seriously doubt it. I learnt that partly on psychedelic drugs." Mullis and biochemist Michael Smith, who had developed other essential ways of manipulating DNA, were jointly awarded the Nobel Prize in Chemistry in 1993, seven years after Mullis and his colleagues at Cetus first put his proposal to practice. Mullis's 1985 paper with R. K. Saiki and H. A.
However, the subsequent era under Leonid Brezhnev, sometimes referred to as the Era of Stagnation, was marked by economic decline, political corruption, and a rigid gerontocracy. Despite efforts to maintain the Soviet Union's superpower status, the economy struggled due to its centralized nature, technological backwardness, and inefficiencies. The vast military expenditures, and the Eastern Bloc halting embezzlement of its resources; further strained the Soviet economy. In the 1980s, Mikhail Gorbachev's policies of glasnost (openness) and perestroika (restructuring) aimed to revitalize the Soviet system but instead accelerated its unraveling. Nationalist movements gained momentum across the Soviet republics and the control of the Communist Party weakened. The failed coup attempt in August 1991 against Gorbachev by hardline communists hastened the end of the Soviet Union, which formally dissolved on 26 December 1991, ending nearly seven decades of Soviet rule.
Sources: en.wikipedia.org
=== Medical use === Urea-containing creams are used as topical dermatological products to promote rehydration of the skin. Urea 40% is indicated for psoriasis, xerosis, onychomycosis, ichthyosis, eczema, keratosis, keratoderma, corns, and calluses. If covered by an occlusive dressing, 40% urea preparations may also be used for nonsurgical debridement of nails. Urea 40% "dissolves the intercellular matrix" of the nail plate. Only diseased or dystrophic nails are removed, as there is no effect on healthy portions of the nail. Urea has been studied as a diuretic. It was first used by Dr. W. Friedrich in 1892. In a 2010 study of ICU patients, urea was used to treat euvolemic hyponatremia and was found safe, inexpensive, and simple. Like saline, urea has been injected into the uterus to induce abortion, although this method is no longer in widespread use. The blood urea nitrogen (BUN) test is a measure of the amount of nitrogen in the blood that comes from urea. It is used as a marker of renal function, though it is inferior to other markers such as creatinine because blood urea levels are influenced by other factors such as diet, dehydration, and liver function. Urea has also been studied as an excipient in drug-coated balloon (DCB) coating formulations to enhance local drug delivery to stenotic blood vessels. Urea, when used as an excipient in small doses (~3 μg/mm2) to coat DCB surface was found to form crystals that increase drug transfer without adverse toxic effects on vascular endothelial cells.
While clearly powerful for assessing proteoforms that fall within its analytical capabilities, MSi-TDP has arguably been most successful in the analysis of the low MW sub-proteome, individual isolated proteins or simple mixtures, and isolated protein complexes having low MW components. Protein identification and proteoform characterization using the MSi-TDP approach can suffer from a similar dynamic range challenge as in BUP "shotgun" LC/MS/MS experiments where the same highly abundant species are repeatedly fragmented . Furthermore, ongoing issues also include: Poor front-end chromatographic resolution of species, even following multiple sequential separation steps, resulting in co-elution of species; The decay in signal-to-noise with increasing proteoform size due to an increase in charge states; the need for better computing infrastructure and software as data sets increase in size, containing complex spectra requiring multiple software tools for downstream analyses that can take multiple hours or longer to complete searches yet can still yield ambiguous identifications. Although MSi-TDP can be operated in relatively high throughput in order to broadly map the low MW sub-proteome, the rate of identifying new proteins is sharply reduced after initial rounds. The effect of chemical noise stemming from various factors such as analyte clustering, multimers, or interfering species, further compounds the arduousness of intact proteofrom detection and analysis using MSi-TDP.
Studies have shown that drinking water from plastic bottles has significantly greater detectable plastic content than tap water. Fecal sample analyses estimate a daily intake of approximately 203–332 MNPs, translating to an annual ingestion rate of around 39,000–52,000 particles. This suggests that daily MNP exposure from food and drink may be substantial, with significant implications for gastrointestinal and systemic health. Estimates of dietary exposure vary across studies due to differences in sampling and detection methods, contributing to uncertainty about typical intake levels.
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.